Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation

Peinemann, Frank; Dalen, Elvira C. van; Enk, Heike; Tytgat, Godelieve A.M.

doi:10.1002/14651858.cd012442.pub2

Cited by 6 publications

(5 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dinutuximab is used in combination with interleukin-2, granulocyte–macrophage colony-stimulating factor, and isotretinoin (13- cis- retinoic acid) for maintenance treatment of pediatric patients with high-risk neuroblastoma who has achieved at least a partial response to first-line multiagent, multimodality therapy 32 . Dinutuximab gave an increased the 2-year event-free survival and overall survival when compared to standard treatment in phase III trials 33 .…”

Section: Discussionmentioning

confidence: 99%

Characterization of glycosphingolipids from gastrointestinal stromal tumours

Santos

Jin

Gazárková

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Gastrointestinal stromal tumours (GISTs) are the major nonepithelial neoplasms of the human gastrointestinal tract with a worldwide incidence between 11 and 15 per million cases annually. In this study the acid and non-acid glycosphingolipids of three GISTs were characterized using a combination of thin-layer chromatography, chemical staining, binding of carbohydrate recognizing ligands, and mass spectrometry. In the non-acid glycosphingolipid fractions of the tumors globotetraosylceramide, neolactotetraosylceramide, and glycosphingolipids with terminal blood group A, B, H, Lex, Lea, Ley and Leb determinants were found. The relative amounts of these non-acid compounds were different in the three tumour samples. The acid glycosphingolipid fractions had sulfatide, and the gangliosides GM3, GD3, GM1, Neu5Acα3neolactotetraosylceramide, GD1a, GT1b and GQ1b. In summary, we have characterized the glycosphingolipids of GISTs and found that the pattern differs in tumours from different individuals. This detailed characterization of glycosphingolipid composition of GISTs could contribute to recognition of new molecular targets for GIST treatment and sub-classification.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of glycosphingolipids from gastrointestinal stromal tumours

Santos

Jin

Gazárková

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…According to the report, there is a unique coincidence of neonatal lupus and NBL (42). In addition, antigen processing and presentation are also involved in the treatment of NBL (43, 44). The chemokine signaling pathway (45, 46) and the cytokine-cytokine receptor interaction (47) also play a role in the occurrence and development of NBL.…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma

et al. 2019

View full text Add to dashboard Cite

Objective: The stratification of neuroblastoma (NBL) prognosis remains difficult. RNA-based signatures might be able to predict prognosis, but independent cross-platform validation is still rare.Methods: RNA-Seq-based profiles from NBL patients were acquired and then analyzed. The RNA-Seq prognostic index (RPI) and the clinically adjusted RPI (RCPI) were successively established in the training cohort (TARGET-NBL) and then verified in the validation cohort (GSE62564). Survival prediction was assessed using a time-dependent receiver operating characteristic (ROC) curve and area under the ROC curve (AUC). Functional enrichment analysis of the genes was conducted using bioinformatics methods.Results: In the training cohort, 10 gene pairs were eventually integrated into the RPI. In both cohorts, the high-risk group had poor overall survival (OS) (P < 0.001 and P < 0.001, respectively) and favorable event-free survival (EFS) (P = 0.00032 and P = 0.06, respectively). ROC curve analysis also showed that the RPI predicted OS (60 month AUC values of 0.718 and 0.593, respectively) and EFS (60 month AUC values of 0.627 and 0.852, respectively) well in both the training and validation cohorts. Clinicopathological indicators associated with prognosis in the univariate and multivariate regression analyses were identified and added to the RPI to form the RCPI. The RCPI was also used to divide populations into different risk groups, and the high-risk group had poor OS (P < 0.001 and P < 0.001, respectively) and EFS (P < 0.05 and P < 0.05, respectively). Finally, the RCPI had higher accuracy than the RPI for the prediction of OS (60 month AUC values of 0.730 and 0.852, respectively) and EFS (60 month AUC values of 0.663 and 0.763, respectively) in both the training and validation cohorts. Moreover, these differentially expressed genes may be involved in certain NBL-related events.Conclusions: The RCPI could reliably categorize NBL patients based on different risks of death.

show abstract

“…Progression of neuroblastoma during or following treatment with anti-GD2 mAbs also may result from insufficient tumor cell exposure to the antibody, a response by immune effector cells that is inadequate to induce ADCC or CDC, or inherent resistance of the patient's neuroblastoma cell line to antibody therapy (75). Nevertheless, a Cochrane Database Systematic Review published in April 2019 concluded that, based on the results of the pivotal phase III ANBL0032 trial, the evidence base favors "dinutuximab-containing immunotherapy compared to standard therapy concerning overall survival and event-free survival in people with high-risk neuroblastoma pre-treated with autologous HSCT" (101).…”

Section: Neuroblastomamentioning

confidence: 99%

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

2020

View full text Add to dashboard Cite

show abstract

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation

Abstract: Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.

Cited by 6 publications

References 73 publications

Characterization of glycosphingolipids from gastrointestinal stromal tumours

Characterization of glycosphingolipids from gastrointestinal stromal tumours

Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Contact Info

Product

Resources

About